Longer-term follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE

被引：0
|
作者：
Marantz, J. [1 ]
Gold, R. [2 ]
Giovannoni, G. [3 ]
Phillips, J. T. [4 ]
Fox, R. J. [5 ]
Zhang, A. [1 ]
机构：
[1] Biogen Inc, Cambridge, MA 02142 USA
[2] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[3] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[4] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA
[5] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P564
引用
收藏
页码：263 / 263
页数：1
相关论文
共 50 条
  • [31] Delayed-release dimethyl fumarate and disability assessed by the multiple sclerosis functional composite: integrated analysis of DEFINE and CONFIRM
    Giovannoni, G.
    Gold, R.
    Kappos, L.
    Arnold, D. L.
    Bar-Or, A.
    Kurukulasuriya, N. C.
    Yang, M.
    Sarda, S. P.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 92 - 92
  • [32] Efficacy of Oral BG-12 (Dimethyl Fumarate) in Patients Newly Diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Analysis of DEFINE and CONFIRM
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Fox, R. J.
    Rana, J.
    Zhang, A.
    Meltzer, L.
    Kurukulasuriya, N. C.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 931 - 932
  • [33] Efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing- remitting multiple sclerosis using a composite measure of disability-Integrated analysis of the phase 3 define and confirm studies
    Phillips, J. Theodore
    Bar-Or, Amit
    Gold, Ralf
    Giovannoni, Gavin
    Fox, Robert J.
    Potts, James
    Marantz, Jing L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP3 - NP4
  • [34] Delayed-release dimethyl fumarate and freedom from measured clinical and neuroradiologic disease activity in relapsing-remitting multiple sclerosis (RRMS) patients: integrated analysis of DEFINE and CONFIRM
    Havrdova, E.
    Gold, R.
    Fox, R. J.
    Kappos, L.
    Phillips, J. T.
    Zhang, A.
    Kurukulasuriya, N. C.
    Sheikh, S. I.
    Viglietta, V.
    Giovannoni, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 459 - 459
  • [35] MRI Outcomes at Seven Years in Relapsing-Remitting Multiple Sclerosis Patients Treated With Delayed-release Dimethyl Fumarate in DEFINE, CONFIRM, and ENDORSE
    Arnold, Douglas L.
    Fox, Robert J.
    Gold, Ralf
    Havrdova, Eva
    Kappos, Ludwig
    Yousry, Tarek
    MacManus, David
    Yang, Lili
    Riester, Katherine
    Taylor, Catherine
    Fay, Monica
    NEUROLOGY, 2017, 88
  • [36] Delayed-release dimethyl fumarate and freedom from measured clinical and neuroradiologic disease activity in relapsing-remitting multiple sclerosis (RRMS) patients: integrated analysis of DEFINE and CONFIRM
    Havrdova, E.
    Gold, R.
    Fox, R. J.
    Kappos, L.
    Phillips, J. T.
    Zhang, A.
    Kurukulasuriya, N. C.
    Sheikh, S. I.
    Viglietta, V.
    Giovannoni, G.
    JOURNAL OF NEUROLOGY, 2014, 261 : S304 - S305
  • [37] Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM
    Fernandez, Oscar
    Giovannoni, Gavin
    Fox, Robert J.
    Gold, Ralf
    Phillips, J. Theodore
    Potts, James
    Okwuokenye, Macaulay
    Marantz, Jing L.
    CLINICAL THERAPEUTICS, 2017, 39 (08) : 1671 - 1679
  • [38] Efficacy and safety of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis patients with cardiovascular disease: integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Havrdova, E.
    Fox, R. J.
    Gold, R.
    Li, J.
    Zhang, A.
    Potts, J.
    Marantz, J. L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 551 - 552
  • [39] Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM
    Fox R.J.
    Gold R.
    Phillips J.T.
    Okwuokenye M.
    Zhang A.
    Marantz J.L.
    Neurology and Therapy, 2017, 6 (2) : 175 - 187
  • [40] Three-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated clinical efficacy data from the DEFINE, CONFIRM, and ENDORSE studies
    Gold, R.
    Phillips, J. T.
    Bar-Or, A.
    Hutchinson, M.
    Kappos, L.
    Zhang, R.
    Yang, M.
    Viglietta, V.
    Sheikh, S. I.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 222 - 222
12345